Lifordi Immunotherapeutics Reports Positive Phase 1 Data for LFD-200 in Autoimmune Disease
Phase 1 data for LFD-200, a subcutaneous glucocorticoid antibody-drug conjugate, shows anti-inflammatory activity without systemic steroid toxicity, with patient dosing ongoing in rheumatoid arthritis.
Lifordi Immunotherapeutics, Inc., a clinical-stage biotechnology company focused on antibody-drug conjugates (ADCs) for autoimmune and inflammatory disorders, presented first-in-human data for its lead candidate LFD-200 at the EULAR 2026 congress in London. The data, derived from healthy participants, indicate that LFD-200 is well tolerated and exhibits dose-responsive anti-inflammatory activity without suppressing serum cortisol levels, a key marker of systemic glucocorticoid toxicity.
The company announced the results on June 8, 2026, following a poster presentation at the European Congress of Rheumatology held June 3-6. LFD-200 is a novel subcutaneously administered ADC that delivers a potent glucocorticoid directly to immune cells, aiming to harness the anti-inflammatory power of steroids while avoiding their well-known systemic side effects. The Phase 1 study in healthy volunteers showed that the drug did not impact cortisol levels, suggesting a favorable safety profile compared to conventional glucocorticoid therapies.
Given the prevalence of autoimmune conditions like rheumatoid arthritis, which affects millions worldwide, the implications of this data are significant. Current glucocorticoid treatments, while effective, are often limited by long-term toxicity, including adrenal suppression, osteoporosis, and metabolic disturbances. LFD-200's targeted delivery could potentially offer a safer alternative for patients requiring sustained anti-inflammatory therapy. The company is now dosing patients with moderate to severe rheumatoid arthritis in the ongoing Phase 1 study, with data expected by year-end 2026.
Lifordi's approach leverages the proven ADC platform, which has been successful in oncology, to address the unmet need in immunology. The company's pipeline also includes ADCs with other payloads, such as antisense oligonucleotides and siRNA, indicating a broader platform potential. Backed by prominent investors including ARCH Venture Partners, Atlas Venture, 5AM Ventures, and Sanofi Ventures, Lifordi is positioned to advance its technology. For more information, visit www.lifordi.com.
The positive Phase 1 results in healthy participants represent an early but promising step toward developing a new class of anti-inflammatory agents. If the ongoing patient study confirms these findings, LFD-200 could become a significant treatment option for rheumatoid arthritis and potentially other autoimmune diseases, offering efficacy without the burden of systemic steroid side effects. The full announcement and additional details are available through Reportable.